The Role of Positron Emission Tomography in Pharmacokinetic Analysis

References

• Haggard H. W. The absorption, distribution and elimination of ethyl ether. I. the amount of ether absorbed in relation to the concentration inhaled and its fate in the body. J. Biol. Chem. 1924; 59: 737–751
   Google Scholar
• Widmark E. M. P. Die theoretischen Grundlagen and die praktische Verwendbarkeit der gerichtlichmedizinischen Alkoholbestimmung. Urban & Schwarzenberg, Berlin 1932
   Google Scholar
• Toerell T. Kinetics of distribution of substances administered to the body. I. the extravascular modes of administration. Arch. Int. Pharmacodyn. 1937; 57: 205–225
   Google Scholar
• Toerell T. Kinetics of distribution of substances administered to the body. II. the intravascular modes of administration. Arch. Int. Pharmacodyn. 1937; 57: 226–240
   Google Scholar
• Pike V W, Palmer Horlock A. J., Perun T. J., Freiberg L. A., Dunnigan D. A., Liss R. H. Preparation of carbon-11 labeled antibiotic-erythromycin lactobionate. J. Chem. Soc. Chem. Comman. 1982; 173–174
   Google Scholar
• Wollmer P., Rhodes C. G., Pike V. W., Silvester D. J., Pride N. B., Sanders A., Palmer A. J., Liss R. H. Measurement of pulmonary erythromycin concentration in patients with lobar pneumonia by means of positron emission tomography. Lancet 1982; 2: 1361–1364
   PubMed Web of Science ®Google Scholar
• Richardson K., Cooper K., Marriott M. S., Tarbit M. H., Troke P. F., Whittle P. J. Design and synthesis of a systemically active agent, fluconazole. Ann. NY Acad. Sci. 1988; 544: 4–11
   PubMedGoogle Scholar
• Richardson K. The discovery and profile of fluconazole. J. Chemother. 1990; 2: 51–54
   PubMed Web of Science ®Google Scholar
• Richardson K., Cooper K., Tarbit M. H., Troke P. F., Whittle P. J. Discovery of fluconazole, a novel antifungal agent. Rev. Infect. Dis. 1990; 3(Suppl)267–271
   Google Scholar
• Van Den Bossche H., Willemsens G., Cools W., Cornelissen F., Lauwers W. F., Van Cutsem J. M. In vitro and in vivo effects of the antimycotic drug ketoconazole on sterol synthesis. Antimicrob. Agents Chemother. 1980; 17: 922–928
   PubMed Web of Science ®Google Scholar
• Van Den Bossche H., Willemsens G., Cools W., Marichal P., Lauwers W. F. Hypothesis on the molecular basis of the antifungal activities of N-substituted imidazoles and triazoles. Biochem. Soc. Trans 1983; 11: 665–667
   PubMed Web of Science ®Google Scholar
• Van Den Bossche H. Biochemical targets for antifungal azolederivative. Hypothesis of the mode of action. Curr. Top. Med. Mycol. 1985; 1: 313–351
   PubMedGoogle Scholar
• Watson P. F., Rose M. E., Ellis S. W., England H., Kelly S. L. Defective sterol C5–6 desaturation and azole resistance: A new hypothesis for the mode of action of azole antifungals. Biochem. Biphys. Res. Commun. 1989; 164: 1170–1175
   PubMed Web of Science ®Google Scholar
• Saag M. S., Dismukes W. E. Azole antifungal agents: Emphasis on new triazoles. Antimicrob. Agents. Chemother. 1988; 32: 1–8
   PubMed Web of Science ®Google Scholar
• Van Cauteren H., Lampo A., Vandenberghe, Vanparys J. P., Coussement W., De Coster R., Marsboom R. Toxicological profile and safety evaluation of antifungal azole derivatives. Mycoses 1989; 32(Suppl. 1)60–66
   PubMedGoogle Scholar
• Conti D. J., Tolkoff-Rubin N. E., Baker G. P., Doran M., Cosimi A. B., Delmonico F., Auchincloss H., Russell P. S., Rubin R. H. Successful treatment of invasive fungal infection with fluconazole in organ transplantation recipients. Transplantation 1989; 47: 692–695
   Google Scholar
• Larsen R. A. Azoles and aids. J. Infect. Dis. 1990; 162: 727–730
   PubMed Web of Science ®Google Scholar
• Powderly W. G., Saag M. S., Cloud G. A., Robinson P., Meyer R. D., Jacobson J. M., Graybill J. R., Sugar A. M., McAuliffe V. J., Follansbee S. E. A controlled trial of fluconazole and amphotericin B to prevent relapse of cryptococcal meningitis in patients with acquired immunodeficiency disease. the NIAID AIDS Clinical Trials Group and Mycoses Study Group. N. Engl. J. Med. 1992; 326: 793–798
   PubMed Web of Science ®Google Scholar
• Saag M. S., Powderly W. G., Cloud G. A., Robinson P., Greico M. H., Sharkey P. K., Thompson S. E., Sugar A. M., Tuazon C. U., Fisher J. F. Comparison of amphotericin B with in the treatment of acute AIDS-associated cryptococcal meningitis. the NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N. Engl. J. Med. 1992; 326: 83–89
   PubMed Web of Science ®Google Scholar
• Larsen R. A., Leal M. A., Chan L. S. Fluconazole compared with amphotericin B plus flucytosine for cryptococcal meningitis in AIDS. A randomized trial. Ann. Intern. Med. 1990; 113: 183–187
   PubMed Web of Science ®Google Scholar
• Humphrey M. J., Jevons S., Tarbit M. H. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole anti-fungal drug, in animals and humans. Antimicrob. Agents Chemother. 1985; 28: 648–653
   PubMed Web of Science ®Google Scholar
• Walsh T. J., Foulds G., Pizzo P. A. Pharmacokinetics and tissue penetration of fluconazole in rabbits. Antimicrob. Agents Chemother. 1989; 33: 467–469
   PubMed Web of Science ®Google Scholar
• Brammer K. W., Farrow P. R., Faulkner J. K. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev. Infect. Dis. 1990; 3(Suppl. 12)318–326
   Google Scholar
• Debruyne D., Ryckelynck J. P., Bigot M. C., Moulin M. Determination of fluconazole in biological fluids by capillary column gas chromatography with a nitrogen detector. J. Pharm. Sci. 1988; 77: 534–535
   PubMed Web of Science ®Google Scholar
• Ebden P., Neill P., Farrow P. R. Sputum levels of fluconazole in humans. Antimicrob. Agents Chemother. 1989; 33: 963–964
   PubMed Web of Science ®Google Scholar
• Foulds G., Brennan D. R., Wajszczuk C., Cantanzaro A., Garg D. C., Knopf W., Rinaldi M., Weidler D. J. Fluconazole penetration into cerebral spinal fluid. J. Clin. Pharmacol. 1988; 28: 363–366
   PubMed Web of Science ®Google Scholar
• Foulds G., Wajszczuk C., Weidler D. J., Garg D. J., Gibson P. Steady state parenteral kinetics of fluconazole in man. Ann. NY Acad. Sci. 1988; 544: 427–430
   PubMedGoogle Scholar
• Livni E., Fischman A. J., Ray S., Sinclair I, Elmaleh D. R., Alpert N. M., Weiss S., Du L., Webb D., Dahl R., Robeson W., Margouleff D., Liss R., Strauss H. W., Rubin R. H. Synthesis of 18F-labeled fluconazole and positron emission tomography in rabbits. Int. J. Appl. Radiat. Isot. Part B 1992; 19: 191–199
   PubMedGoogle Scholar
• Fischman A. J., Alpert N. M., Livni E., Ray S., Sinclair I., Elmaleh D. R., Weiss, Correia J. A., Webb D., Liss R., Strauss H. W., Rubin R. H. Pharmacokinetics of 18F-labeled fluconazole in rabbits with candidal infections studied with positron emission tomography. J. Pharm. Exp. Ther. 1991; 259: 1351–1359
   PubMed Web of Science ®Google Scholar
• Fischman A. J., Alpert N. M., Livni E., Ray S., Sinclair I., Callahan R. J., Correia J. A., Webb D., Strauss H. W., Rubin R. H. Pharmacokinetics of 18F-labeled fluconazole in normal human subjects studied with positron emission tomography. Antimicrob. Agents Chemother. 1993; 37: 1270–1277
   PubMed Web of Science ®Google Scholar
• Galgiani J. N. Susceptibility of Candida albicans and other yeasts to fluconazole: Relation between in vitro and in vivo studies. Rev. Infect. Dis. 1990; 12(Suppl. 3)S272–275
   PubMedGoogle Scholar
• Marriot M. S., Richardson K. The discovery and mode of action of fluconazole. Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents, R. A. Fromberg. J. R. Prous Science Publishers, Barcelona 1987; 81–92
   Google Scholar
• Rogers T. E., Galgiani J. N. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob. Agents Chemother. 1986; 30: 418–422
   PubMed Web of Science ®Google Scholar
• Hughes C. E., Bennett R. L., Tuna I. C., Beggs W. H. Activities of fluconazole (UK 49,858) and ketoconazole against ketoconazole-susceptible and -resistant Candida albicans. Antimicrob. Agents Chemother. 1988; 32: 209–212
   PubMed Web of Science ®Google Scholar
• Berry A. J., Rinaldi M. G., Graybill J. R. Use of high-dose fluconazole as salvage therapy for cryptococcal meningitis in patients with AIDS. Antimicrob. Agents Chemother. 1992; 36: 690–692
   PubMed Web of Science ®Google Scholar
• Livni E., Babich J., Alpert N. M., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Correia J. A., Strauss H. W., Rubin R. H., Fischman A. J. Synthesis and biodistribution of 18F-labeled fleroxacin. Nucl. Med. Biol. 1993; 20: 81–87
   PubMed Web of Science ®Google Scholar
• Fischman A. J., Livni E., Babich J., Alpert N., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Callahan R. J., Correia J. A., Strauss H. W., Rubin R. H. Pharmacokinetics of 18F-labeled fleroxacin in rabbits with E. coli infections studied with positron emission tomography. Antimicrob. Agents Chemother. 1992; 36: 2286–2292
   PubMed Web of Science ®Google Scholar
• Fischman A. J., Livni E., Babich J., Alpert N. M., Liu Y. Y., Thom E., Cleeland R., Prosser B. L., Correia J. A., Strauss H. W., Rubin R. H. Pharmacokinetics of [18F] fleroxacin in normal human subjects studied with positron emission tomography. Antimicrob. Agents Chemother. 1993; 37: 2144–2152
   PubMed Web of Science ®Google Scholar
• Fischman A. J., Livni E., Babich J. W., Alpert N. M., Bonab A., Chodosh S., McGovern F., Kamitsuka P., Liu Y. Y., Cleeland R., Prosser B. L., Correia J. A., Rubin R. J. Pharmacokinetics of [18F] fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied with positron emission tomography. Antimicrob. Agents Chemother. 1996; 40: 659–664
   PubMed Web of Science ®Google Scholar
• Tewson T. J. Synthesis of fluorine-18 lomefloxacin, a fluorinated quinolone antibiotic. J. Labeled Compds. Radiopharm. 1993; 32: 145–146
   Google Scholar
• Babich J. W., Rubin R. H., Graham W. A., Wilkinson R. A., Vincent J., Fischman A. J. 18F-Labeling and biodistribution of the novel fluoro-quinolone antimicrobial agent, trovafloxacin (CP-99,214). Nuci. Med. Biol. 1996; 23: 995–998
   PubMed Web of Science ®Google Scholar
• Farde L., Halldin C., Stone-Elander S., Sedvall G. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology (Berl.) 1987; 92: 278–284
   PubMed Web of Science ®Google Scholar
• Farde L., Wiesel F. A., Nordstrom A. L., Sedvall G. D1-and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology (Berl.) 1989; 99: S28–31
   PubMed Web of Science ®Google Scholar
• Farde L. Selective D1-and D2-dopamine receptor blockade both induces akathisia in humans-a Pet study with [11C]SCH 23390 and [11C]raclopride. Psychopharmacology (Berl.) 1992; 107: 23–29
   PubMed Web of Science ®Google Scholar
• Farde L., Nordstrom A. L., Wiesel F. A., Pauli S., Halldin C., Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozpaine. Relation to extrapyramidal side effects. Arch. Gen. Psychiatry 1992; 49: 538–544
   PubMed Web of Science ®Google Scholar
• Syrota A., Paillotin G., Davy J. M., Aumont M. C. Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography. Life Sci. 1984; 35(9)937–945
   PubMed Web of Science ®Google Scholar
• Frey K. A., Hichwa R. D., Ehrenkaufer R. L., Agranoff B. W. Quantitative in vivo receptor binding. III. Tracer kinetic modeling of muscarinic cholinergic receptor binding. Proc. Natl. Acad. Sci. U.S.A. 1985; 82(19)6711–6715
   PubMed Web of Science ®Google Scholar
• Wong D. F., Gjedde A., Wagner H. N., Jr., Dannals R. F., Douglass K. H., Links J. M., Kuhar M. J. Quantification of Neuroreceptors in the living human brain. II. Inhibition studies of receptor density and affinity. J. Cereb. Blood Flow Metab. 1986; 6(2)147–153
   PubMed Web of Science ®Google Scholar
• Farde L., Eriksson L., Blomquist G., Halldin C. Kinetic analysis of central [11C]raclopride binding to D2-dopamine receptors studied by PET—a comparison to the equilibrium analysis. J. Cereb. Blood Flow Metab. 1989; 9(5)696–708
   PubMed Web of Science ®Google Scholar
• Delforge J., Loch C., Hantraye P., Stulzaft O., Khalili-Varasteh M., Maziere M., Syrota A., Maziere B. Kinetic analysis of central [76Br]bromolisuride binding to dopamine D2 receptors studied by PET. J. Cereb. Blood Flow Metab. 1991; 11(6)914–925
   PubMed Web of Science ®Google Scholar
• Morris E. D., Alpert N. M., Fischman A. J. Comparison of two compartmental models for describing receptor ligand kinetics and receptor availability in multiple injection PET studies. J. Cereb. Blood Flow Metab. 1996; 16: 841–853
   PubMed Web of Science ®Google Scholar
• Huang S. C., Bahn M. M., Barrio J. R., Hoffman J. M., Satyamurthy N., Hawkins R. A., Mazziotta J. C., Phelps M. E. A double-injection technique for in vivo measurement of dopamine D2-receptor density in monkeys with 3-(2′-[18F]fluoroethyl) spiperone and dynamic positron emission tomography. J. Cereb. Blood Flow Metab. 1989; 9(6)850–858
   PubMed Web of Science ®Google Scholar
• Farde L., Hall H., Ehrin E., Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231(4735)258–261
   PubMed Web of Science ®Google Scholar
• Huang S. C., Barrio J. R., Phelps M. E. Neuroreceptor assay with positron emission tomography: equilibrium versus dynamic approaches. J. Cereb. Blood Flow Metab. 1986; 6(5)515–521
   PubMed Web of Science ®Google Scholar
• Fischman A. J., Bonab A. A., Babich J. W., Alpert N. M., Rauch S. L., Elmaleh D. R., Shoup T. M., Williams S. A., Rubin R. H. Positron emission tomographic analysis of central 5HT2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J. Pharm. Exp. Ther. 1996; 279: 939–947
   PubMed Web of Science ®Google Scholar
• Mintun M. A., Raichle M. E., Kilbourne M. R., Wooton G. F., Welch M. J. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann. Neurol. 1984; 15: 217–227
   PubMed Web of Science ®Google Scholar
• Petit-Taboue M. C., Landeau B., Osmont A., Tillet I., Barre L., Baron J. C. Estimation of neocortical serotonon-2-receptor binding potential by single dose 18F-setoperone kinetic PET data analysis. J. Nucl. Med. 1996; 37: 95–104
   PubMed Web of Science ®Google Scholar
• Patlak C. S., Blasberg R. G. Fensternmacher 1983 Graphical evaluation of blood-to-brain transfer constants in multiple-time uptake data. J. Cereb. Blood Flow Metab., 3: 1–7
   PubMed Web of Science ®Google Scholar
• Logan J., Fowler J. S., Volkow N. D., Wolf A. P., Dewey S. L., Schlyer D. J., MacGregor R. R., Hitzemann R., Bendriem B., Gatley S. J., Christman D. R. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J. Cereb. Blood Flow Metab. 1990; 10: 740–747
   PubMed Web of Science ®Google Scholar
• Halldin C., Stone-Elander S., Farde L., Ehrin E., Fasth K. J., Langstrom B., Sedvall G. Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emmision tomography. Int. J. Bad. Appl. Instrum. [A] 1986; 37: 1039–1043
   PubMedGoogle Scholar
• McQuade R. D., Duffy R. A., Coffin V. L., Chipkin R. E., Barnett A. In vivo binding of SCH 39166: a D-1 selective antagonist. J. Pharmacol. Exp. Ther. 1991; 257(1)42–49
   PubMed Web of Science ®Google Scholar
• Wagner H. N., Jr., Burns H. D., Dannals R. F., Wong D. F., Langstrom B., Duelfer T., Frost J. J., Raven H. T., Links J. M., Rosenbloom S. B., Lukas S. E., Kramer A. V., Kuhar M. J. Imaging dopamine receptors in the human brain by positron tomography. Science 1983; 221: 1264–1266
   PubMed Web of Science ®Google Scholar
• Maziere B., Loc'h C., Hantraye P., Guillon R., Duquesnoy N., Soussaline F., Naquet R., Comar D., Maziere M. 76Brbromospiroperidol: a new tool for quantiative in-vivo imaging of neuroleptic receptors. Life Sci 1984; 35(13)1349–1356
   PubMed Web of Science ®Google Scholar
• Farde L., Hall H., Ehrin E., Sedcvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231(4735)258–261
   PubMed Web of Science ®Google Scholar
• Maziere B., Loc'h C, Stulzaft O., Hantraye P., Ottaviani M., Comar D., Maziere M. [76Br]bromolisuride: A new tool for quantiative in vivo imaging of D-2 dopamine receptors. Eur. J. Pharmacol. 1986; 127(3)239–247
   PubMed Web of Science ®Google Scholar
• Blin J., Sette G., Fiorelli M., Bletry O., Elghozi J. L., Crouzel C., Baron J. C. A method for the in vivo investigation of the serotonergic 5-HT2 receptors in the human cerebral cortex using positron emission tomography and 18F-labeled setoperone. J. Neurochem. 1990; 54(5)1744–1754
   PubMed Web of Science ®Google Scholar
• Wong D. F., Lever J. R., Hartig P. R., Dannals R. F., Villemagne V., Hoffman B. J., Wilson A. A., Ravert H. T., Links J. M., Scheffel U. Localization of serotonin 5-HT2 receptors in living human brain by positron emission tomography using Nl-([11C]-methyl)-2-Br-LSD. Synapse 1987; 1(5)393–398
   PubMed Web of Science ®Google Scholar
• Maziere M., Hantraye P., Kaijima M., Dodd R., Guibert B., Prenant C., Sastre J., Crouzel M., Comar D., Naquet R. Visualization by positron emission tomography of the apparent regional heterogeneity of central type benzodiazepine receptors in the brain of living baboons. Life Sci. 1985; 36(17)1609–1616
   PubMed Web of Science ®Google Scholar
• Charbonneau P., Syrota S., Crouzel C., Valois J. M., Prenant C., Crouzel M. Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography. Circulation 1986; 73(3)476–483
   PubMed Web of Science ®Google Scholar
• Frost J. J., Mayberg H. S., Fisher R. S., Douglass K. I-I., Dannals R. F., Links J. M., Wilson A. A., Ravert H. T., Rosenbaum A. E., Synder S. H., Wagner H. N., Jr. Mu-receptors measured by positron emission tomography are increased in temporal lobe epilepsy. Ann. Neurol. 1988; 23: 231–237
   PubMed Web of Science ®Google Scholar
• Jones A. K., Luthra S. K., Maziere B., Pike V. W., Loc'h C., Crouzel C., Syrota A., Jones T. Regional cerebral opioid receptor studies with [11C]diprenorphine in normal volunteers. J. Neurosci. Methods 1988; 23(2)121–129
   PubMed Web of Science ®Google Scholar
• Pert C. B., Danks J. A., Channing M. A., Eckelman W. C., Larson S. M., Bennett J. M., Burke T. R., Jr., Rice K. C. 3-[18F]Acetylcyclofoxy: a useful probe for the visualization of opiate receptors in living animals. FEBS Lett. 1984; 177(2)281–286
   PubMed Web of Science ®Google Scholar
• Syrota A., Paillotin G., Davy J. M., Aumont M. C. Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography. Life Sci. 1984; 35(9)937–945
   PubMed Web of Science ®Google Scholar
• Dannals R. F., Langstrom B., Ravert H. T., Wilson A. A., Wagner H. N., Jr. Synthesis of radiotracers for studying muscarinic cholinergic receptors in the living human brain using positron emission tomography: [11C]dexetimide and [11C]levetimide. Int. J. Rod. Appl. Instrum. [A] 1988; 39(4)291–295
   PubMedGoogle Scholar
• Frey K. A., Koeppe R. A., Mulholland G. K., Jewett D. M., Hichwa R. D., Agranoff B. W., Kuhl D. E. Muscarinic receptor imaging in human brain using [C-11] scopolamine and positron emission tomography. J. Nucl. Med. 1988; 29(5)808, (abstract)
   Google Scholar
• Dewey S. L., MacGregor R. R., Brodie J. D., Bendriem B., King P. T., Volkow N. D., Schyler D. J., Fowler J. S., Wolfe A. P., Gatley S. J. Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine. Synapse 1990; 5(3)213–223
   PubMed Web of Science ®Google Scholar
• Syrota A. In vivo investigation of myocardial perfusion, metabolism and receptors by positron emission tomography. Int. J. Microcirc. Clin. Exp. 1989; 8(4)411–422
   PubMedGoogle Scholar